v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Expense

The following table presents the Company’s segment expense for the three months ended March 31, 2025 and 2024:

 

Oncology Segment

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Revenue

 

$

5,392

 

 

$

6,471

 

Less R&D expenses:

 

 

 

 

 

 

       TNG462 direct program expenses

 

 

5,461

 

 

 

5,086

 

       TNG456 direct program expenses

 

 

1,324

 

 

 

-

 

       TNG260 direct program expenses

 

 

1,730

 

 

 

2,236

 

       TNG961 direct program expenses

 

 

2,221

 

 

 

-

 

       TNG908 direct program expenses*

 

 

1,712

 

 

 

4,258

 

       TNG348 direct program expenses**

 

 

-

 

 

 

3,300

 

       Discovery direct program expenses

 

 

4,679

 

 

 

5,511

 

       Personnel-related expenses

 

 

13,850

 

 

 

12,798

 

       Facilities and other related expenses

 

 

5,465

 

 

 

4,876

 

Less G&A and other expenses:

 

 

 

 

 

 

       Other segment expenses (a)

 

 

8,826

 

 

 

6,320

 

Segment net loss

 

$

(39,876

)

 

$

(37,914

)

*In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.